Heptares Co-Founder Resigns as VP and CSO of Parent Company Sosei Post author:Sam Post published:January 18, 2018 Post category:BioPharma Dr. Marshall will leave Sosei at the end of February 2018. Source: BioSpace You Might Also Like Karolinska Development AB Release: Pharma Portfolio Company Announces FDA 510(K) Clearance For Marketing Of OSSDSIGN Cranial For Sale In The U.S.A. January 19, 2017 The Medicines Company To Announce Fourth-Quarter And Full-Year 2016 Financial Results On February 28, 2017 February 16, 2017 Medidata Solutions, Inc. Release: Chugai Deploys Ravex To Modernize Post-Marketing Surveillance June 29, 2017
Karolinska Development AB Release: Pharma Portfolio Company Announces FDA 510(K) Clearance For Marketing Of OSSDSIGN Cranial For Sale In The U.S.A. January 19, 2017
The Medicines Company To Announce Fourth-Quarter And Full-Year 2016 Financial Results On February 28, 2017 February 16, 2017
Medidata Solutions, Inc. Release: Chugai Deploys Ravex To Modernize Post-Marketing Surveillance June 29, 2017
